Bicyclo Ring System Having The Hetero Ring As One Of The Cyclos (e.g., Chromones, Etc.) Patents (Class 514/456)
  • Patent number: 11654118
    Abstract: A composition comprising a therapeutically effective amount of a cannabinoid and protocatechuic acid is provided. The disclosure further provides a method of treating inflammation comprising administering a composition comprising a therapeutically effective amount of a cannabinoid and protocatechuic acid to a patient in need thereof. The disclosure further provides a method of treating inflammation including administering a composition including protocatechuic acid and a composition including a cannabinoid to a patient in need thereof. In embodiments, the composition including protocatechuic acid and the composition including a cannabinoid may be administered simultaneously within about 60 minutes of each other. In embodiments, the cannabinoid includes Cannabidiol (CBD).
    Type: Grant
    Filed: September 13, 2022
    Date of Patent: May 23, 2023
    Inventor: Lanny Leo Johnson
  • Patent number: 11648222
    Abstract: Disclosed herein are methods for treating a cancer comprising administering to a subject in need thereof an effective dose of a CYP26-resistant retinoic acid receptor (RAR) alpha (RAR?) selective agonist, whereby as a result of the treatment the tumor burden is reduced in the subject and cancer stem cells resident in the bone marrow are substantially reduced.
    Type: Grant
    Filed: December 29, 2020
    Date of Patent: May 16, 2023
    Assignees: IO Therapeutics, Inc., The Johns Hopkins Univercity
    Inventors: Gabriel Ghiaur, Richard J. Jones, Salvador Alonso, Roshantha A. Chandraratna
  • Patent number: 11622988
    Abstract: The present disclosure provides an extract of early-harvested Citrus reticulata fruit, and a method for reducing lipid accumulation by using the extract of early-harvested Citrus reticulata fruit. The extract of early-harvested Citrus reticulata fruit includes tetramethylisoscutellarein.
    Type: Grant
    Filed: May 19, 2021
    Date of Patent: April 11, 2023
    Assignee: TCI CO., LTD.
    Inventor: Yung-Hsiang Lin
  • Patent number: 11617725
    Abstract: A composition comprising a therapeutically effective amount of a cannabinoid and protocatechuic acid is provided. The disclosure further provides a method of treating inflammation comprising administering a composition comprising a therapeutically effective amount of a cannabinoid and protocatechuic acid to a patient in need thereof. The disclosure further provides a method of treating inflammation including administering a composition including protocatechuic acid and a composition including a cannabinoid to a patient in need thereof. In embodiments, the composition including protocatechuic acid and the composition including a cannabinoid may be administered simultaneously within about 60 minutes of each other. In embodiments, the cannabinoid includes Cannabidiol (CBD).
    Type: Grant
    Filed: April 20, 2022
    Date of Patent: April 4, 2023
    Inventor: Lanny Leo Johnson
  • Patent number: 11612616
    Abstract: Compositions comprising aldehyde functional monoterpenoids in combination with 3,3?,4?,7-tetrahydroxyflavone, zinc, and a 5-beta-D-Ribofuranosylpicolineamide adenine-dinucleotide molecule are provided for treating viral infections, e.g., coronavirus infections such as COVID-19.
    Type: Grant
    Filed: May 3, 2021
    Date of Patent: March 28, 2023
    Inventor: William B. Coe
  • Patent number: 11583514
    Abstract: Provided herein is a pharmaceutical composition comprising at least one isoflavonoid. Also provided herein are methods of treating cancer, sensitizing cancer cells, and inducing apoptosis in cancer cells by administering such compositions.
    Type: Grant
    Filed: September 17, 2020
    Date of Patent: February 21, 2023
    Assignee: MEI Pharma, Inc.
    Inventors: George Jeoffreys, Alison Johnson, Andrew Heaton, Ofir Moreno
  • Patent number: 11554153
    Abstract: Compositions and methods for bone health, cartilage health or both, are disclosed that include preparing and utilizing a mixture of at least one Morus extract enriched for one or more prenylated flavonoids, at least one Scutellaria extract enriched for one or more free-B-ring flavonoids, and at least one Acacia extract enriched for one or more flavans.
    Type: Grant
    Filed: March 9, 2020
    Date of Patent: January 17, 2023
    Assignee: Unigen, Inc.
    Inventors: Qi Jia, Ping Jiao, Mesfin Yimam, Teresa Horm
  • Patent number: 11547715
    Abstract: A drug that contains chlorogenic acid is effective in treating chordoma. When administered to a patient in need thereof, chlorogenic acid can significantly inhibit the proliferation of chordoma cells, reduce the expression level of multi-drug resistance gene MDR1 of chordoma cells, reverse the multi-drug resistance of chordoma cells, and effectively treat chordoma disease.
    Type: Grant
    Filed: December 27, 2018
    Date of Patent: January 10, 2023
    Assignee: SICHUAN JIUZHANG BIOLOGICAL SCIENCE AND TECHNOLOGY CO., LTD.
    Inventors: Jie Zhang, Yazhuo Zhang, Mengtian Zhang
  • Patent number: 11547691
    Abstract: Described herein are Dendrilla membranosa compounds and derivatives thereof. Also described herein are formulations that can contain an amount of one or more Dendrilla membranosa compounds or derivatives thereof and a carrier. Also described herein are methods of administering one or more Dendrilla membranosa compound and/or derivative thereof or a formulation thereof to a subject in need thereof.
    Type: Grant
    Filed: December 16, 2019
    Date of Patent: January 10, 2023
    Assignees: UNIVERSITY OF SOUTH FLORIDA, THE UAB RESEARCH FOUNDATION
    Inventors: Bill J. Baker, Lindsey N. Shaw, Andrew Jason Shilling, Alexandre Jean Bory, Jessie Allen (Adams), Charles Dunkle Amsler, Jr., James Bruce McClintock
  • Patent number: 11504349
    Abstract: The present invention relates to: a 4-benzopyranone derivative and a pharmaceutically acceptable salt, solvate, racemate, or stereoisomer thereof; a composition for preventing, alleviating or treating TNF-related diseases, containing the same as an active ingredient; and a method for treating TNF-related diseases, a reagent composition for inhibiting TNF, and a method for inhibiting TNF, all of which use the same. The compositions can be orally administered so as not to cause injection side effects, do not cause immunological tolerance, and can effectively inhibit a TNF activity by being directly bound to TNF while facilitating co-administering with a conventional oral preparation and dosage control.
    Type: Grant
    Filed: July 12, 2018
    Date of Patent: November 22, 2022
    Assignee: ILAB
    Inventors: Tae-Hwe Heo, Kye Jung Shin
  • Patent number: 11497719
    Abstract: Disclosed are a cannabinoid composition and an application of the same in preparing a medicine for treating neurodegenerative diseases, so as to solve the drawbacks of conventional medicines such as serious side effects and degraded therapeutic effect after long-term administration. The cannabinoid composition includes: cannabidiol and cannabigerol, a mass ratio of the cannabidiol to the cannabigerol ranging from 1:1 to 1:10, or from 1:0.3 to 1:0.5, or from 1:0.5 to 1:0.7, or from 1:07 to 1:1.
    Type: Grant
    Filed: January 27, 2022
    Date of Patent: November 15, 2022
    Inventors: Chendong Zou, Hei Tai, Guijiang Wang, Wan Xiao, Sui Huang
  • Patent number: 11491136
    Abstract: Neuropeptide FF receptor modulators based on a proline scaffold are provided which offer NPFF receptor potencies in the nanomolar range and antagonistic selectivity for the NPFF1 receptor. Methods, compounds and compositions for modulating the function of neuropeptide FF receptors are provided for pharmacotherapies capable of influencing conditions or disorders affected by the neuropeptide FF receptors.
    Type: Grant
    Filed: February 13, 2018
    Date of Patent: November 8, 2022
    Assignee: RESEARCH TRIANGLE INSTITUTE
    Inventors: Yanan Zhang, Thuy Nguyen
  • Patent number: 11491134
    Abstract: A composition for inhibiting skin cell proliferation and/or anti-inflammation is provided. The composition for inhibiting skin cell proliferation and/or anti-inflammation includes: apigenin and luteolin, wherein a weight ratio of the apigenin to the luteolin is about 1.5-25:1, or a mole ratio of the apigenin to the luteolin is about 1.5-25:1. Moreover, the apigenin and the luteolin have a synergistic effect on inhibiting skin cell proliferation and/or anti-inflammation.
    Type: Grant
    Filed: December 31, 2019
    Date of Patent: November 8, 2022
    Assignee: INDUSTRIAL TECHNOLOGY RESEARCH INSTITUTE
    Inventors: I-Hong Pan, Ming-Han Li, Kai-An Chuang, Shu-Fang Wen
  • Patent number: 11458117
    Abstract: Disclosed are the uses of compositions containing not less than 10% w/w of Oroxylin A, not less than 10% w/w of Baicalein and not less than 2% w/w of Chrysin in inhibiting the activity and expression of ? secretase. The invention also discloses the reduction of amyloid content in PS-70 cells using the abovementioned composition. Further, the invention mentions the use of the composition for the therapeutic management of ? secretase mediated disorders.
    Type: Grant
    Filed: June 14, 2018
    Date of Patent: October 4, 2022
    Assignee: SAMI LABS LIMITED
    Inventors: Muhammed Majeed, Kalyanam Nagabhushanam
  • Patent number: 11395814
    Abstract: The invention provides safe and efficacious treatments for Female Sexual Disorders, genitopelvic pain/penetration disorders; vulvovaginal atrophy, vestibulodynia, dyspareunia, sexual interest/arousal disorder, low female libido, and female orgasmic disorder.
    Type: Grant
    Filed: April 14, 2020
    Date of Patent: July 26, 2022
    Inventor: Wendy Anne Epstein
  • Patent number: 11364220
    Abstract: Compounds described herein are inhibitors of retinoic add inducible P450 (CYP26) enzymes, and are useful for treating diseases that are responsive to retinoids. Certain compounds have retinoid activity, are resistant to CYP26-mediated catabolism, and are used for treating diseases that are responsive to retinoids.
    Type: Grant
    Filed: November 26, 2020
    Date of Patent: June 21, 2022
    Assignee: Queen's University at Kingston
    Inventors: Donald Andrew Cameron, Martin Petkovich, Toni Kristian Rantanen, Victor Snieckus, Johnathan Board, Suneel Singh, Ashishkumar Jayantilal Maheta
  • Patent number: 11337934
    Abstract: A composition comprising a therapeutically effective amount of a cannabinoid and protocatechuic acid is provided. The disclosure further provides a method of treating inflammation comprising administering a composition comprising a therapeutically effective amount of a cannabinoid and protocatechuic acid to a patient in need thereof. The disclosure further provides a method of treating inflammation including administering a composition including protocatechuic acid and a composition including a cannabinoid to a patient in need thereof. In embodiments, the composition including protocatechuic acid and the composition including a cannabinoid may be administered simultaneously within about 60 minutes of each other. In embodiments, the cannabinoid includes Cannabidiol (CBD).
    Type: Grant
    Filed: April 8, 2021
    Date of Patent: May 24, 2022
    Inventor: Lanny Leo Johnson
  • Patent number: 11337935
    Abstract: Disclosed herein are compounds and compositions thereof which find use in increasing stability of TTR tetramers reducing its tendency to misfold and form aggregates. Also provided herein are methods for using these compounds and compositions for increasing stability of TTR and thereby decreasing aggregate formation by TTR. Also disclosed herein are methods to screen for candidate compounds that increase stability of TTR. Also disclosed herein are heterobifunctional compounds that include a TTR binding compound connected to a targeting moiety via a linker, for use in disrupting PPIs of a target protein.
    Type: Grant
    Filed: March 25, 2019
    Date of Patent: May 24, 2022
    Inventors: Isabella A. Graef, Mamoun M. Alhamadsheh
  • Patent number: 11330829
    Abstract: An oil or fat for tempering type chocolate capable of enhancing and maintaining original flavors (milk taste, sweet taste, and cacao flavor, etc.) of chocolate is described, being obtained by blending therein 0.3 to 15% of a randomly transesterified oil of which a raw material is an oil or fat having a content of saturated fatty acids of 5 to 50% in the constituent fatty acids thereof and by further containing 5 to 50 ppm of malonyl isoflavone glycoside. A chocolate in which the oil or fat is blended is also described.
    Type: Grant
    Filed: October 1, 2014
    Date of Patent: May 17, 2022
    Assignee: FUJI OIL HOLDINGS INC.
    Inventors: Masako Okochi, Masayuki Matsui, Chie Nagashima, Chika Aramaki
  • Patent number: 11312695
    Abstract: Methods and compositions are provided for increasing muscle hypertrophy, e.g., through the administration of novel combinations of natural products that inhibit SIRT1.
    Type: Grant
    Filed: February 23, 2021
    Date of Patent: April 26, 2022
    Assignees: The Regents of the University of California, University of Birmingham
    Inventors: Keith Baar, Andrew Philp, Simon Schenk
  • Patent number: 11298334
    Abstract: Disclosed is the use of isothiocyanate compounds. In particular, disclosed is the use of a compound as shown by Formula (I) or a derivative as shown by Formula (II) in the manufacture of a composition or preparation for preventing and/or treating hyperlipidemia. The compound of the present invention can reduce the levels of triglycerides and low density lipoproteins in the serum of mammals (such as rats and humans), increase the level of high density lipoproteins in the serum, and reduce the level of total bilirubin in the serum of mammals (such as rats and humans).
    Type: Grant
    Filed: April 20, 2017
    Date of Patent: April 12, 2022
    Assignee: JC (WUXI) COMPANY, INC.
    Inventors: Jingcai Cheng, Chunxia Zhang, Zhiwei Cheng
  • Patent number: 11298307
    Abstract: The present invention relates to a transparent or semitransparent cosmetic composition in which the stability of amentoflavone is enhanced, and more particularly, to a transparent or semitransparent cosmetic composition, wherein a water-soluble amentoflavone-oligomer complex, in which amentoflavone is encapsulated in a hollow structure of an oligomer structure, is stabilized in a second agent containing a polyhydric alcohol, a two-liquid-type container is used to mix first and second agents before use, and hydrotrope is contained in the first agent to increase the mixing stability of the first and second agents and thereby enhance the stability of amentoflavone.
    Type: Grant
    Filed: March 26, 2018
    Date of Patent: April 12, 2022
    Assignee: Amorepacific Corporation
    Inventors: Byung Ryol Paik, Soon Ae An, Joon Young Hwang, Yong Jin Kim, Byung Fhy Suh
  • Patent number: 11273144
    Abstract: The present invention relates to compounds and compositions and their applications as pharmaceuticals for treating, preventing, or reversing injury to skeletal or cardiac muscles, for treating or preventing diseases relating to the structure and function of skeletal or cardiac muscle, and for inducing regeneration or restructuring of skeletal or cardiac muscle as a means of treating diseases relating to abnormalities in skeletal or cardiac muscle structure and function in a human or animal subject. Further aspects relate to the same or similar applications for bone and bone diseases.
    Type: Grant
    Filed: January 14, 2020
    Date of Patent: March 15, 2022
    Assignee: EPIRIUM BIO INC.
    Inventors: George Frederic Schreiner, Guillermo Ceballos, Sundeep Dugar
  • Patent number: 11241406
    Abstract: Disclosed herein are compositions and methods for acutely raising nitric oxide levels in a subject. In one example, the composition can include, an effective amount of a NOS dependent source of nitric oxide; an effective amount of a NOS independent source of nitric oxide; and an effective amount of a myeloperoxidase inhibitor; wherein the composition acutely raises nitric oxide levels in a subject above a level provided by the available sources of nitric oxide in the subject prior to administration of the composition. Further presented is a method of treating a subject for a condition or disorder that is response to nitric oxide therapy, including: acutely raising nitric oxide levels in a subject by simultaneously increasing biosynthesis of nitric oxide, increasing nitrate/nitrite levels, and inhibiting myeloperoxidase activity.
    Type: Grant
    Filed: August 28, 2016
    Date of Patent: February 8, 2022
    Assignee: Nature's Sunshine Products, Inc.
    Inventors: Matthew L. Tripp, Clinton J. Dahlberg, John G. Babish, Mohan Kaadige, Wei Gao
  • Patent number: 11207313
    Abstract: The present invention relates to a pharmaceutical composition for oral administration comprising a non-bile farnesoid X receptor (FXR) agonist 2-[(1R,3R,5S)-3-({5-cyclopropyl-3-[2-(trifluoromethoxy)phenyl]-1,2-oxazol-4-yl}methoxy)-8-azabicyclo[3.2.1]octan-8-yl]-4-fluoro-1,3-benzothiazole-6-carboxylic acid, or a pharmaceutically acceptable salt thereof, and at least one lipid excipient; to a capsule for oral administration comprising said pharmaceutical composition; to the use of said pharmaceutical composition for the treatment of a FXR mediated disorder or condition; and to a process for preparing said pharmaceutical composition.
    Type: Grant
    Filed: September 10, 2018
    Date of Patent: December 28, 2021
    Assignee: Novartis AG
    Inventors: Claus Dieter Bischoff, Sonali Bose, Geoffrey Gogniat
  • Patent number: 11185527
    Abstract: There is a continuing need for methods and compositions relating to hormone-receptor-dependent cancers, including pharmaceutical compositions including one or more compounds having activity against steroid hormone-receptor-dependent cancer and methods of treatment of a steroid hormone-receptor-dependent cancer in a subject using said pharmaceutical compositions. ELK1 is a steroid hormone receptor tethering, protein that is implicated in hormone receptor dependent cancers. Compositions and methods according to aspects of the present invention inhibit the association of steroid hormone receptors with ELK1 providing activity against steroid hormone-receptor-dependent cancer.
    Type: Grant
    Filed: June 26, 2018
    Date of Patent: November 30, 2021
    Assignee: Wayne State University
    Inventor: Manohar Ratnam
  • Patent number: 11147791
    Abstract: An object of the present invention is to provide a novel composition for use in activating a sympathetic nerve. The present invention provides a composition for use in activating a sympathetic nerve, comprising a polyphenol as an active ingredient. The polyphenol comprises 25% by mass or more of monomeric to tetrameric polyphenols, and the monomeric to tetrameric polyphenols include at least catechin, epicatechin, procyanidin B2, procyanidin B5, procyanidin C1 and cinnamtannin A2.
    Type: Grant
    Filed: November 28, 2017
    Date of Patent: October 19, 2021
    Inventors: Kazuji Tamura, Hiroki Ohara
  • Patent number: 11135261
    Abstract: Provided are liquid and powder grape extracts having elevated phenolic content. The extracts can be made from grape seeds, grape skins, or a combination thereof. In some instances, extracts may be blends of grape seed extracts and grape skin extracts. Methods of manufacturing such extracts area also provided. Such methods involve controlled temperature conditions to increase yield of phenolic compounds in the extracts. Methods of using the extraction for treating subjects are also provided, including treatment of cancer and end-organ damage relating to hypertension.
    Type: Grant
    Filed: April 3, 2017
    Date of Patent: October 5, 2021
    Assignee: PIEDMONT RESEARCH & DEVELOPMENT CORPORATION
    Inventor: Jerry Wayne Smith
  • Patent number: 11110105
    Abstract: The present invention relates to the fields of medicine and cancer treatment. The invention more specifically relates to new compounds which are typically for use as a medicament. In particular, the invention relates to the use of these new compounds for increasing the presentation, typically the production and presentation, of Pioneer Translation Products (PTPs)-derived antigens by cancer cells in a subject, and inducing or stimulating an immune response in the subject. The present disclosure also relates to uses of such compounds, in particular to prepare a pharmaceutical composition and/or to allow or improve the efficiency of a cancer therapy in a subject in need thereof. The invention also discloses methods for preventing or treating cancer, cancer metastasis and/or cancer recurrence in a subject. The present invention in addition provides kits suitable for preparing a composition according to the present invention and/or for implementing the herein described methods.
    Type: Grant
    Filed: April 11, 2018
    Date of Patent: September 7, 2021
    Assignee: INSTITUT GUSTAVE ROUSSY
    Inventors: Sébastien Apcher, Alison Pierson, Mathilde Boulpicante, Zafiarisoa Dolor Renko, Mouad Alami, Romain Darrigrand
  • Patent number: 11098053
    Abstract: Disclosed are daidzein analogs having the formula (I). Also disclosed are compositions, include a disclosed daidzein analogs, methods of preventing or treating bone disease or bone injury and/or stimulating bone growth, in a subject that include administering to the subject an effective amount of disclosed daidzein analog. Disclosed are isolated mesenchymal stem cell that has been altered by treatment a disclosed daidzein analog, daidzein, glycinol, glyceollin I, or glyceollin II, to increase the osteogenic potential of the mesenchymal stem cells.
    Type: Grant
    Filed: April 4, 2014
    Date of Patent: August 24, 2021
    Assignees: THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND, XAVIER UNIVERSITY OF LOUISIANA, THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY OF AGRICULTURE
    Inventors: Amy Strong, Stephen Boue, Matthew Burow, Bruce Bunnell, Quan Jiang, Shilong Zheng, Guangdi Wang
  • Patent number: 11091499
    Abstract: The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof; (I) or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, wherein the variables are as defined herein. The present invention further provides pharmaceutical compositions comprising such compounds; and methods of using such compounds for treating joint damage or injury in a mammal, for inducing hyaline cartilage production or for inducing differentiation of chondrogenic progenitor cells into mature chondrocytes.
    Type: Grant
    Filed: June 7, 2018
    Date of Patent: August 17, 2021
    Assignee: Novartis AG
    Inventors: Ha-Soon Choi, Jiqing Jiang, James Paul Lajiness, Bao Nguyen, Hank Michael James Petrassi
  • Patent number: 11090286
    Abstract: The present invention provides methods and compositions for treating or preventing breast cancer with S-equol. The method and compositions are particularly suited to treating triple-negative breast cancer. The S-equol may be administered alone or in combination with one or more cytotoxic or immunotherapeutic compound or molecule.
    Type: Grant
    Filed: April 15, 2019
    Date of Patent: August 17, 2021
    Assignee: THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: Rong Li, Bin Yuan, Tyler Curiel
  • Patent number: 11083197
    Abstract: An herbicidal composition comprising one or more compounds of Formula I: where R1 and R2 are H or taken together with the carbon atoms to which the are attached form a furane ring; R3 and R4 each independently represent H, —OH or —O—(C1-C4) alkyl; and R5 is H, (C1-C4) alkyl, —(C1-C2) alkylene-O-glucoside or —COOH; and an agriculturally acceptable vehicle. There is also disclosed a method for weed control by application of compounds of Formula I and the use of the composition for controlling weeds.
    Type: Grant
    Filed: December 30, 2016
    Date of Patent: August 10, 2021
    Assignees: Investigaciones Biologicas en Agroquimicos Rosario S.A., The United States of America, as represented by the Secretary of Agriculture
    Inventors: Gustavo M. Sosa, Lucia M. Travaini, Helmut Walter, Charles Cantrell, Stephen Duke, Nestor Carrillo, Eduardo Ceccarelli
  • Patent number: 11058665
    Abstract: The present invention relates to methods for treating brain metastasis by inhibiting gap junction functionality. It is based, at least in part, on the discovery that cancer cells expressing Protocadherin 7 and Connexin 43 form gap junctions with astrocytes that promote the growth of brain metastases, and that inhibition of Protocadherin 7 and/or Connexin 43 expression in cancer cells reduce progression of brain metastases. It is further based on the discovery that treatment with gap junction inhibitors tonabersat and meclofenamate inhibited progression of brain metastatic lesions and enhanced the anti-cancer activity of the conventional chemotherapeutic agent, carboplatin.
    Type: Grant
    Filed: September 13, 2019
    Date of Patent: July 13, 2021
    Assignee: MEMORIAL SLOAN-KETTERING CANCER CENTER
    Inventors: Joan Massague, Adrienne Boire, Qing Chen
  • Patent number: 11052124
    Abstract: The present disclosure provides an extract of early-harvested Citrus reticulata fruit, and a method for reducing lipid accumulation by using the extract of early-harvested Citrus reticulata fruit. The extract of early-harvested Citrus reticulata fruit includes tetramethylisoscutellarein.
    Type: Grant
    Filed: August 7, 2019
    Date of Patent: July 6, 2021
    Assignee: TC1 CO., LTD.
    Inventor: Yung-Hsiang Lin
  • Patent number: 11040045
    Abstract: This invention relates to the use of the combination of 25-hydroxyvitamin D3 (“25-OH D3”) and antioxidants/anti-inflammatories (ascorbic acid, vitamin E and at least one carotenoid) to make a pharmaceutical, nutraceutical or food supplement which can ameliorate various problems observed in humans connected with polycystic ovarian syndrome and cardiovascular diseases. Pharmaceuticals, nutraceuticals and food supplements containing the 25-OH D3 and antioxidants/anti-inflammatories and premixes are also provided.
    Type: Grant
    Filed: April 24, 2020
    Date of Patent: June 22, 2021
    Assignee: DSM IP ASSETS B.V.
    Inventors: Shuen Ei Chen, Thau Kiong Chung, Daniel Raederstorff, Wolfgang Schalch
  • Patent number: 11033553
    Abstract: An energy-promoting composition includes a stimulant component such as caffeine, a vasodilator component, an energy source including an exogenous ketone body component, and optionally a nootropic component. The separate components beneficially and synergistically interact with one another enhances the overall energy-promoting effect of the composition more rapidly and to a greater degree than if one or more of the components are omitted. The energy-promoting composition is also formulated to minimize the crash effect common to stimulants such as energy drinks.
    Type: Grant
    Filed: April 15, 2020
    Date of Patent: June 15, 2021
    Assignee: AXCESS GLOBAL SCIENCES, LLC
    Inventor: Gary Millet
  • Patent number: 11020372
    Abstract: The invention relates to novel methods and compositions for safely reducing negative side effects of cancer treatments. These methods and compositions comprise administering to a patient a composition comprising one or more of the following: curcumin (derived from turmeric), epigallocatechin-3-gallate (EGCG, enriched in green tea), glucosinolates (enriched in cruciferous vegetables) and/or derivatives thereof, such as sulforaphane (SFN), alone or combined with a ketogenic diet or a modified ketogenic diet. Also the current invention relates to a composition comprising medium chain triglycerides (MCT), Epigallocatechin-3-gallate, curcumin, compositions comprising glucosinolates and/or derivatives thereof, such as sulforaphane (SFN).
    Type: Grant
    Filed: March 23, 2016
    Date of Patent: June 1, 2021
    Assignee: UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED
    Inventors: Loic Pierre Deleyrolle, Brent Allan Reynolds
  • Patent number: 11000502
    Abstract: Copper based antibacterial agents are described based on amphiphilic copper complexes formed between copper and hydroxypyrones, such as maltol. In further aspects, the present invention relates to PEG based-ointments showing that they are particularly effective for topical delivery of amphiphilic complexes of copper. In particular, PEG ointments were shown to limit bacterial growth, even when in the absence of copper agent. However, this bacteriostatic effect is shown herein to become a true biocidal effect when copper hydroxypyrones are added to the PEG.
    Type: Grant
    Filed: February 6, 2018
    Date of Patent: May 11, 2021
    Assignee: United Kingdom Research and Innovation
    Inventors: Jonathan Joseph Powell, Nuno Jorge Rodrigues Faria, Carlos Andre Passos Bastos
  • Patent number: 10993958
    Abstract: Compositions comprising aldehyde functional monoterpenoids in combination with 3,3?,4?,7-tetrahydroxyflavone, zinc, and a 5-beta-D-Ribofuranosylpicolineamide adenine-dinucleotide molecule are provided for treating viral infections, e.g., coronavirus infections such as COVID-19.
    Type: Grant
    Filed: May 22, 2020
    Date of Patent: May 4, 2021
    Inventor: William B. Coe
  • Patent number: 10980772
    Abstract: Disclosed herein are “ketannabis” (or “ketonnabis”) compositions including a combination of: (1) tetrahydrocannabinol (THC); (2) a ketone body component such as beta-hydroxybutyrate (BHB) and/or acetoacetate; and (3) a dietetically or pharmaceutically acceptable carrier. Also disclosed herein are methods of using such ketannabis compositions for producing desired physiological effects. The ketannabis compositions beneficially enhance the euphoric effects of THC without aggravating common side effects or even acting to reduce common side effects such as anxiety, disruption of short-term memory, appetite increases, heart rate increases, and blood pressure changes.
    Type: Grant
    Filed: February 11, 2019
    Date of Patent: April 20, 2021
    Assignee: AXCESS GLOBAL SCIENCES, LLC
    Inventor: Gary Millet
  • Patent number: 10959979
    Abstract: Compounds capable of, or usable in, killing cancer cells, and/or modulating a biological activity of a chemokine, and/or inhibiting a kinase, and/or treating diseases and disorders associated with a biological activity of a chemokine and/or cell migration, and/or treating disease and disorders such as cancer and inflammatory diseases and disorders, are provided herein. The compounds are listed in Tables 2, 4 and 5, and/or are represented by Formulae I, IV, V and VI, as defined in the specification. Methods utilizing these compounds are also provided.
    Type: Grant
    Filed: May 7, 2020
    Date of Patent: March 30, 2021
    Assignee: Biokine Therapeutics Ltd.
    Inventors: Amnon Peled, Michal Abraham Karni, Orly Eizenberg
  • Patent number: 10952965
    Abstract: The present disclosure is directed to surface-modified particles and to methods of making and using the same.
    Type: Grant
    Filed: May 15, 2009
    Date of Patent: March 23, 2021
    Assignees: Baxter International Inc., Baxter Healthcare SA
    Inventors: Barrett Rabinow, Shawn F. Bairstow, Mahesh V. Chaubal, Sarah Lee, Jane Werling
  • Patent number: 10925918
    Abstract: A composition for food and a fat absorption inhibitor, each including a seaweed polyphenol and a tea extract.
    Type: Grant
    Filed: January 21, 2015
    Date of Patent: February 23, 2021
    Assignee: FUJIFILM Cornoration
    Inventors: Yuriko Oda, Fumitaka Ueda
  • Patent number: 10888574
    Abstract: The present disclosure relates to a method for suppressing obesity, which includes administering to a subject a compound represented by the following formula wherein n is an integer of 1 to 5; when n is 1, R1 is —OH or —O-glycosyl; when n is an integer of 2 to 5, one R1 is —OH and the other R1(s) is/are —O-glycosyl; and R2 is -glycosyl.
    Type: Grant
    Filed: September 28, 2018
    Date of Patent: January 12, 2021
    Assignee: KINJIRUSHI CO.. LTD.
    Inventors: Isao Okunishi, Tomoe Kato
  • Patent number: 10874634
    Abstract: Compounds described herein are inhibitors of retinoic acid inducible P450 (CYP26) enzymes, and are useful for treating diseases that are responsive to retinoids. Certain compounds have retinoid activity, are resistant to CYP26-mediated catabolism, and are used for treating diseases that are responsive to retinoids.
    Type: Grant
    Filed: December 13, 2017
    Date of Patent: December 29, 2020
    Assignee: Queen's University at Kingston
    Inventors: Donald Andrew Cameron, Martin Petkovich, Toni Kristian Rantanen, Victor Snieckus, Johnathan Board, Suneel Singh, Ashishkumar Jayantilal Maheta
  • Patent number: 10849862
    Abstract: To provide a therapeutic agent for cancer having a higher therapeutic effect. A therapeutic agent for cancer, containing: at least one selected from the group consisting of curcumin and a derivative thereof; and at least one selected from the group consisting of an anti-PD-1 antibody, an anti-PD-L1 antibody, and an anti-PD-L2 antibody in combination.
    Type: Grant
    Filed: December 24, 2015
    Date of Patent: December 1, 2020
    Assignee: THERAVALUES CORPORATION
    Inventors: Yutaka Kawakami, Tomonori Yaguchi, Taeko Hayakawa, Atsushi Imaizumi
  • Patent number: 10844073
    Abstract: Provided herein are palladium-mediated coupling reactions useful in the preparation of ketone-containing organic molecules. The provided methods can be used for the preparation of natural products and pharmaceutical agents, including Eribulin, halichondrins, and analogs thereof. The present invention also provides novel halichondrin analogs which can be prepared via the palladium-mediated coupling reactions. The novel halichondrin analogs can be used in the prevention and/or treatment of diseases or conditions (e.g., proliferative diseases such as cancer).
    Type: Grant
    Filed: July 1, 2019
    Date of Patent: November 24, 2020
    Assignee: President and Fellows of Harvard College
    Inventors: Jung Hwa Lee, Yoshito Kishi, Ayumi Osawa, Zhanjie Li
  • Patent number: 10786531
    Abstract: The present disclosure generally relates to the medical use of compositions comprising a mineral salt and a sulfonic acid for prevention and/or treatment of one or more mucosal diseases, disorders, or conditions or one or more dermal diseases, disorders, or conditions.
    Type: Grant
    Filed: June 24, 2019
    Date of Patent: September 29, 2020
    Assignee: BMG PHARMA SPA
    Inventors: William A. Goolsbee, Jeffrey L. Lillard
  • Patent number: 10765660
    Abstract: A pharmaceutical composition for the prevention and treatment of cancer with specific flavanoid-based compounds selected from among the groups of Flavone, Flavanone and Flavanol, a method for the prevention and treatment of cancer and inflammation using the specific flavonoid-based pharmaceutical compositions, a method for isolating the flavonoid-based pharmaceutical compositions from raw plant material, and a method for synthesizing said specific flavonoid-based pharmaceutical compositions.
    Type: Grant
    Filed: June 27, 2017
    Date of Patent: September 8, 2020
    Inventors: Henry Lowe, Ngeh J. Toyang, Joseph Bryant